ArrowMark Colorado Holdings LLC lowered its holdings in bluebird bio Inc (NASDAQ:BLUE) by 38.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 221,541 shares of the biotechnology company’s stock after selling 140,284 shares during the period. ArrowMark Colorado Holdings LLC’s holdings in bluebird bio were worth $39,456,000 as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in the company. Nomura Asset Management Co. Ltd. acquired a new stake in shares of bluebird bio in the fourth quarter worth $356,000. Rock Springs Capital Management LP increased its position in shares of bluebird bio by 28.6% in the fourth quarter. Rock Springs Capital Management LP now owns 45,000 shares of the biotechnology company’s stock worth $8,015,000 after acquiring an additional 10,000 shares in the last quarter. Driehaus Capital Management LLC acquired a new stake in shares of bluebird bio in the fourth quarter worth $243,000. Signaturefd LLC acquired a new stake in shares of bluebird bio in the fourth quarter worth $294,000. Finally, AXA increased its position in shares of bluebird bio by 126.4% in the fourth quarter. AXA now owns 24,900 shares of the biotechnology company’s stock worth $4,435,000 after acquiring an additional 13,900 shares in the last quarter.
A number of equities research analysts recently weighed in on the stock. Canaccord Genuity reaffirmed a “buy” rating and set a $250.00 price target on shares of bluebird bio in a report on Thursday, February 1st. Maxim Group reaffirmed a “hold” rating and set a $200.00 price target on shares of bluebird bio in a report on Thursday, February 22nd. Morgan Stanley reaffirmed an “equal weight” rating and set a $152.00 price target (up from $151.00) on shares of bluebird bio in a report on Monday, February 26th. BTIG Research raised their price target on shares of bluebird bio to $250.00 and gave the company a “buy” rating in a report on Thursday. Finally, CIBC assumed coverage on shares of bluebird bio in a report on Thursday, December 21st. They set a “market perform” rating for the company. Three research analysts have rated the stock with a sell rating, eight have given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $187.60.
bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported ($2.52) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.68) by ($0.84). The company had revenue of $4.17 million for the quarter, compared to analyst estimates of $7.11 million. bluebird bio had a negative return on equity of 28.09% and a negative net margin of 947.42%. bluebird bio’s revenue was up 169.0% on a year-over-year basis. During the same period in the prior year, the business earned ($1.88) earnings per share. research analysts anticipate that bluebird bio Inc will post -8.25 EPS for the current year.
In other bluebird bio news, CEO Nick Leschly sold 5,435 shares of the firm’s stock in a transaction on Friday, January 5th. The shares were sold at an average price of $173.38, for a total transaction of $942,320.30. Following the completion of the transaction, the chief executive officer now directly owns 171,009 shares of the company’s stock, valued at approximately $29,649,540.42. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Susanna Gatti High sold 17,262 shares of the firm’s stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $195.91, for a total transaction of $3,381,798.42. Following the transaction, the chief operating officer now directly owns 28,512 shares of the company’s stock, valued at $5,585,785.92. The disclosure for this sale can be found here. Over the last three months, insiders have sold 198,998 shares of company stock valued at $37,659,935. 3.90% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: This story was published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/3252469/arrowmark-colorado-holdings-llc-sells-140284-shares-of-bluebird-bio-inc-blue.html.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio Inc (NASDAQ:BLUE).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.